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Abstract
Introduction: Prescription opioids were responsible for approximately 17,000 deaths in the U.S. 
in 2016. One in five prescription opioid deaths also involve alcohol. Drinkers who misuse 
prescription opioids (i.e., use without a prescription or use only for the experience or feeling it 
caused) are at heightened risk of overdose. However, little is known about the relationship between 
drinking patterns and prescription opioid misuse.
Methods: Data were analyzed from the 160,812 individuals (aged ≥12 years) who responded to 
questions about prescription opioid misuse and alcohol consumption in the 2012, 2013, or 2014 
National Survey on Drug Use and Health (analyzed in 2017–2018). The prevalence of self-
reported past 30-day prescription opioid misuse was assessed by sociodemographic characteristics, 
other substance use (i.e., cigarettes, marijuana), and drinking patterns. Multiple logistic regression 
was used to calculate AORs.
Results: From 2012 to 2014, 1.6% (95% CI=1.5, 1.7) of all individuals aged ≥12 years 
(estimated 4.2 million) and 3.5% (95% CI=3.3, 3.8) of binge drinkers (estimated 2.2 million) 
reported prescription opioid misuse. Prescription opioid misuse was more common among binge 
drinkers than non-drinkers (AOR=1.7, 95% CI=1.5, 1.9). Overall, the prevalence of prescription 
opioid misuse increased significantly with binge drinking frequency (p-value <0.001).
Conclusions: More than half of the 4.2 million people who misused prescription opioids during 
2012–2014 were binge drinkers, and binge drinkers had nearly twice the odds of misusing 
prescription opioids compared with non-drinkers. Widespread use of evidence-based strategies for 
preventing binge drinking might reduce opioid misuse and overdoses involving alcohol.
INTRODUCTION
Prescription opioids were involved in approximately 17,000 deaths in the U.S. in 2016,1 
tripling since 1999.2,3 The number of opioid prescriptions written also tripled during this 
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time, substantially increasing opioid availability.4 In addition, prescription opioid overdose, 
abuse, and dependence cost the U.S. $78.5 billion in 2013, including healthcare claims, 
substance use disorder treatment, criminal justice costs, and lost productivity.5 
Consequently, the opioid overdose epidemic has been declared a public health emergency.6
Compared with those who use opioids as prescribed, people who misuse prescription opioids 
(defined in this analysis as using an opioid without a prescription, or using these drugs only 
for the experience or feeling it caused) may consume higher doses of these drugs, use them 
more frequently, or both, increasing the risk of non-fatal and fatal overdoses.7–9 One study 
analyzed data from the Drug Abuse Warning Network on emergency department (ED) visits 
and found that there were 305,900 ED visits due to prescription opioid misuse in 2008, 
which was double the number reported in 2004.10
An important, though generally underrecognized risk factor for opioid misuse is alcohol 
consumption, particularly excessive drinking. For example, a study using 2006 data from the 
National Survey on Drug Use and Health (NSDUH) found that, compared with non-
drinkers, men and women who consumed alcohol during the previous year were 70% and 
90% more likely to misuse opioids during the previous year, respectively.11 However, the 
authors did not assess the association between prescription opioid misuse and alcohol use by 
sociodemographic characteristics other than gender, nor did they examine this relationship 
by drinking patterns (e.g., binge drinking). Another study using the 2001–2002 National 
Epidemiologic Survey on Alcohol Related Conditions found that 1.1% of past-year drinkers 
who did not binge drink, and 2.2% of binge drinkers who did not have alcohol abuse or 
dependence, misused prescription opioids during the past year.12 After controlling for sex, 
age, and race or ethnicity, past-year drinkers who did not binge drink, and binge drinkers 
who did not meet DSM-IV criteria for alcohol abuse or dependence, were 1.8 and 3.6 times 
more likely to report past-year prescription opioid misuse than non-drinkers, respectively. 
However, the authors did not assess this relationship by sociodemographic characteristics, 
nor did they control for differences in annual household income, which has been shown to 
be associated with both binge drinking and prescription opioid misuse.13,14 In addition, the 
authors were unable to fully assess the relationship between binge drinking and prescription 
opioid misuse because of the exclusion of respondents who met DSM-IV criteria for alcohol 
abuse or dependence from their binge drinking population.
Alcohol consumption has also been associated with prescription opioid overdoses. In 2010, 
one in five opioid-involved deaths in the U.S. also involved alcohol.15 In addition, alcohol 
was involved in 18% of the prescription opioid-involved ED visits in 2010, and more than 
40% of these prescription opioid-involved overdoses were among ED patients aged 30–54 
years.15 Similarly, in 2008, a nationwide study found that 20% of hospitalizations for 
prescription opioid overdoses among young adults aged 18–24 years involved excessive 
alcohol use (i.e., ICD-9-CM codes 980, E860, 303.0, 305.0, or 790.3), which is similar to 
the proportion of opioid overdoses among people in this age group that involved excessive 
alcohol use in 1999 (17%).16 The concurrent use of alcohol and prescription opioids is 
concerning because both have a depressant effect on the central nervous system, and the 
concurrent use of these drugs could therefore lead to a dangerous drug interaction that could 
significantly increase the risk of respiratory depression and death.17–21
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The purpose of this study is to assess the association between past 30-day drinking patterns 
(e.g., current, non-binge drinking and binge drinking) and prescription opioid misuse among 
U.S. adults and adolescents. In addition, this study seeks to examine the relationship 
between binge drinking frequency and prescription opioid misuse.
METHODS
Study Sample
The NSDUH is a nationally representative, cross-sectional household survey of the non-
institutionalized U.S. adult and adolescent population aged ≥12 years residing in the 50 
states and the District of Columbia that is conducted annually by the Substance Abuse and 
Mental Health Services Administration. For each state and the District of Columbia, a 
multistage probability sample was independently determined. A computer-assisted personal 
interview and audio computer-assisted self-interview (to improve respondents’ privacy 
during visits to households and group living residences) were used to collect survey data. 
Respondents were given $30 as compensation for their participation in the survey. More 
details on the NSDUH methods are available elsewhere.22
Data for this study were pooled from the 2012, 2013, and 2014 NSDUH public use files to 
smooth out random fluctuations in self-reported alcohol use and prescription opioid misuse, 
particularly when assessing prescription opioid misuse by drinking patterns and 
sociodemographic characteristics. Weighted response rates were 73.0% (2012), 71.7% 
(2013), and 71.2% (2014). There was a total of 204,048 survey respondents during the 3-
year study period. The study sample included the 160,812 (78.8%) of the total respondents 
who answered questions about the misuse of prescription opioids and alcohol consumption.
Measures
Respondents were categorized into three drinking categories (i.e., non-drinkers, current/non-
binge drinkers, and binge drinkers) on the basis of responses to the following questions: (1) 
During the past 30 days, on how many days did you drink one or more drinks of an alcoholic 
beverage?; (2) During the past 30 days, that is since [datefill], on how many days did you 
have 5 or more drinks on the same occasion? By “occasion,” we mean at the same time or 
within a couple of hours of each other. (question for males); and (3) During the past 30 days, 
that is since [datefill], on how many days did you have 4 or more drinks on the same 
occasion? (question for females). Non-drinking was defined as not consuming an alcoholic 
drink on any day during the past 30 days, including lifetime abstainers. Current drinking was 
defined as consuming one or more alcoholic drinks on ≥1 days during the past 30 days. 
Binge drinking was defined as consuming five or more drinks (for males) or four or more 
drinks (for females), per occasion, on ≥1 day during the past 30 days. Current/non-binge 
drinking was defined as current drinking below binge levels. Binge drinking frequency was 
defined as the number of days a respondent consumed five or more drinks (for males) or four 
or more drinks (for females) per occasion during the past 30 days.
In the survey section on use of prescription medications, the NSDUH interviewers asked a 
series of questions about use of specific types of opioids (e.g., codeine, hydrocodone, and 
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morphine). This study assessed prescription opioid misuse on the basis of responses to the 
following question: How long has it been since you last used any prescription pain reliever 
that was not prescribed for you or that you took only for the experience or feeling it caused? 
Prescription opioid misuse was defined as the use of an opioid without a prescription, or the 
use of these drugs only for the experience or feeling it caused at least one time during the 
past 30 days.
Statistical Analysis
The prevalence of past 30-day prescription opioid misuse, non-drinking, current/non-binge, 
and binge drinking were assessed overall and by sociodemographic characteristics and other 
substance use (i.e., past 30-day cigarette use or marijuana use). Prescription opioid misuse 
was also assessed by drinking pattern, sociodemographic characteristics, and other substance 
use. The relationship between binge drinking frequency and prescription opioid misuse was 
assessed overall and by age group. NSDUH survey weights and design variables were used 
to compute prevalence estimates and 95% CIs. A new population weight was created for this 
3-year dataset by dividing the single-year dataset weights by three. P-values were calculated 
using Pearson’s chi-square tests (p-values <0.05 were used to assess statistical significance). 
When measuring the association between prescription opioid misuse and binge drinking, 
multiple logistic regression was used to adjust ORs for potential confounders, including age 
group, sex, race or ethnicity, total annual family income, rural or urban status,22 cigarette 
use,23,24 and marijuana use.23–25
Respondents who were missing data on sociodemographic characteristics or on drinking 
patterns were excluded from item-specific analyses (missing data were <3%). Data were 
analyzed using Stata, version 14.2 (analyses were conducted in 2017–2018).
RESULTS
During 2012–2014, 1.6% (95% CI=1.5, 1.7) of U.S. adults and adolescents, or an estimated 
4.2 million people, reported past 30-day prescription opioid misuse (Table 1). Prescription 
opioid misuse was most common among males (1.9%, 95% CI=1.7, 2.1), those aged 18–25 
years (2.9%, 95% CI=2.7, 3.1) and 26–34 years (2.8%, 95% CI=2.4, 3.1), among those with 
an annual family income of <$20,000 (2.3%, 95% CI=2.1, 2.6), and among those with no 
health insurance coverage (2.9%, 95% CI=2.6, 3.2). Current/non-binge drinking was most 
common among adults aged ≥50 years (33.4%, 95% CI=32.6, 34.3); white, non-Hispanic 
adults (31.1%, 95% CI=30.5, 31.6); college graduates (43.4%, 95% CI=42.5, 44.4); and 
those with an annual family income of >$75,000 (36.9%, 95% CI=36.1, 37.6). Binge 
drinking was most common among males (29.6%, 95% CI=29.0, 30.2); those aged 18–25 
years (40.4, 95% CI=39.7, 41.1) and 26–34 years (38.8%, 95% CI=38.0, 39.7); white, non-
Hispanic adults (25.8%, 95% CI=25.3, 26.3); and adults with some college education 
(28.7%, 95% CI=28.0, 29.5).
The prevalence of prescription opioid misuse was similar among non-drinkers (1.0%, 95% 
CI=0.9, 1.2) and current/non-binge drinkers (1.0%, 95% CI=0.9, 1.2), but was 3.5 times 
higher among binge drinkers (3.5%, 95% CI=3.3, 3.8; Table 2). This translates to an 
estimated 2.2 million binge drinkers engaging in prescription opioid misuse in the past 30 
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days. Across all sociodemographic groups, prescription opioid misuse was more common 
among binge drinkers than among non-drinkers and current/non-binge drinkers. Prescription 
opioid misuse was most common among non-drinkers aged 18–25 years (1.5%, 95% 
CI=1.3, 1.8) and 26–34 years (1.7%, 95% CI=1.4, 2.2), current/non-binge drinkers aged 12–
17 years (3.6%, 95% CI=2.8, 4.7), and binge drinkers aged 12–17 years (8.1%, 95% CI=6.8, 
9.7). However, about 1.4 million (65%) of the estimated 2.2 million binge drinkers, who 
reported misusing prescription opioids, were aged ≥26 years.
Among binge drinkers, prescription opioid misuse was most common among black, non-
Hispanic people (4.6%, 95% CI=3.7, 5.6; Table 2). Among binge drinkers, having no health 
insurance coverage (prevalence of prescription opioid misuse: 5.6%, 95% CI=4.9, 6.4) or 
having public health insurance (prevalence of prescription opioid misuse: 5.0%, 95% 
CI=4.2, 6.0) was also associated with a higher prevalence of prescription opioid misuse, 
whereas having private health insurance coverage was associated with a lower rate of 
prescription opioid misuse (2.6%, 95% CI=2.4, 2.9). The prevalence of prescription opioid 
misuse was inversely related to education and family income across all drinking categories, 
but was similar among males and females. Across all drinking categories, prescription 
opioid misuse was more common among those who used marijuana than those who smoked 
cigarettes. Prescription opioid misuse was also more common among binge drinkers who 
smoked cigarettes (5.6%, 95% CI=5.1, 6.0) or used marijuana (10.1%, 95% CI=9.3, 11.1) 
than among non-drinkers and current/non-binge drinkers who used these substances, 
respectively.
After adjusting for potential confounders, binge drinkers had 1.7 times greater odds (95% 
CI=1.5, 1.9, p-value <0.001) of reporting prescription opioid misuse than non-drinkers 
(Table 3). Current/non-binge drinking was not associated with prescription opioid misuse 
(AOR=1.0, 95% CI=0.8, 1.1, p-value=0.580).
The overall prevalence of prescription opioid misuse increased significantly with the 
frequency of binge drinking (p-value <0.001), ranging from 2.4% (95% CI=2.2, 2.7) among 
those who reported binge drinking one to two times during the past 30 days to 6.5% (95% 
CI=5.6, 7.6) among those who reported binge drinking ten or more times (Figure 1). When 
stratified by age group, the prevalence of presciption opioid misuse increased significantly 
with the frequency of binge drinking among those aged 12–49 years (p-value <0.001), as 
well as among adults aged ≥50 years (p-value=0.04). Among adults aged ≥50 years, the 
prevalence of opioid misuse was similar for those who reported either binge drinking five to 
nine times (3.2%, 95% CI=1.8, 5.5) or ten or more times (2.8%, 95% CI=1.5, 5.0) during the 
previous 30 days.
DISCUSSION
The results of this study indicate that more than half (2.2 million) of the estimated 4.2 
million adolescents and adults who reported past 30-day misuse of prescription opioids 
during 2012–2014 were binge drinkers. Binge drinkers had nearly twice the odds of 
misusing prescription opioids compared with non-drinkers, even after controlling for other 
factors that could affect the relationship between binge drinking and prescription opioid 
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misuse. Prescription opioid misuse was most common among youth aged 12–17 years who 
binge drank, but about 1.4 million (65%) of the estimated 2.2 million binge drinkers who 
reported prescription opioid misuse were aged 26 years or older. The prevalence of 
prescription opioid misuse increased with the frequency of binge drinking, particularly 
among youth and young adults.
Across drinking categories, this study generally did not find differences in the prevalence of 
prescription opioid misuse by sex or by rural or urban status. However, among binge 
drinkers, this study found a higher prevalence of prescription opioid misuse among those 
with lower levels of education, lower household incomes, and those who were either covered 
by publicly funded health insurance or were uninsured. This finding is consistent with the 
findings of other research that has shown that prescription opioid misuse is generally more 
common among low-income populations, including those on Medicaid.26 It is also 
consistent with a recent study showing that binge drinkers with lower household incomes 
consume significantly more total binge drinks per binge drinker annually than those with 
higher household incomes (532.3 drinks versus 419.0 drinks, respectively).13 However, 
people with higher household incomes (e.g., $75,000 or more) have a higher prevalence of 
binge drinking than those with lower household incomes (less than $25,000), underscoring 
the importance of addressing binge drinking among the entire population.13
The finding that the prevalence of prescription opioid misuse generally increased with binge 
drinking frequency is consistent with literature showing that the likelihood of engaging in 
alcohol-related health risk behaviors increases with the number of binge drinking occasions. 
For example, a study of U.S. high school students found a positive relationship between 
binge drinking frequency and use of other drugs, including tobacco, marijuana, cocaine, and 
inhalants (prescription opioid misuse was not assessed).27
Adult binge drinkers tend to binge about once a week on average and consume an average of 
seven drinks per binge,13 and people who misuse prescription opioids also report doing so 
about once a week (an average of 54 days a year).7 This is concerning given that the risk of a 
dangerous interaction between alcohol and opioids is likely to be greatest among those who 
are misusing opioids and binge drinking frequently and at high intensity.
The odds of prescription opioid misuse among binge drinkers being nearly twice that of non-
drinkers suggests the importance of population-level policies to reduce binge drinking. The 
U.S. Community Preventive Services Task Force recommends several effective strategies for 
reducing binge drinking, including increasing alcohol taxes,28 regulating the density of 
alcohol outlets,29 and having commercial host liability laws.30 In addition, the U.S. 
Preventive Services Task Force recommends screening and brief intervention for adults as a 
strategy to reduce excessive alcohol use.31 This intervention may also be effectively 
administered electronically (also known as e–screening and brief intervention) using 
computers, tablets, smartphones, and other electronic tools in a variety of settings (e.g., 
primary care clinics, health departments, and on college campuses).32 Effective strategies to 
reduce overdoses involving prescription opioids includeexpanding safe, evidence-based pain 
treatment and decreasing excessive prescribing that may leave unused opioids available for 
potential misuse, safe prescribing practices, as described in the Centers for Disease Control 
Esser et al. Page 6
Am J Prev Med. Author manuscript; available in PMC 2019 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and Prevention Guideline for Prescribing Opioids for Chronic Pain,33 as well as strategies to 
prevent and treat opioid use disorder,34 and reverse opioid overdoses.35
Finally, the 2015–2020 U.S. Dietary Guidelines for Americans indicate that some people 
should not drink at all, including those who are taking medications that could interact with 
alcohol, as well as youth under age 21 years and women who are pregnant or might be 
pregnant.36 The U.S. Food and Drug Administration has also advised healthcare 
professionals to avoid prescribing opioids to patients using alcohol or other central nervous 
system depressants.17 Therefore, adult drinkers aged 21 years or older should only do so in 
moderation (i.e., consume up to one drink per day for women and up to two drinks per day 
for men), or not drink at all, particularly while taking prescription opioids.17,36
Future research examining the relationship between evidence-based alcohol policies (e.g., 
increasing alcohol taxes28 and regulating the density of alcohol outlets30), total binge drinks 
per binge drinker, and the risk of opioid overdoses in states could help guide the prevention 
of opioid misuse and opioid overdoses involving alcohol. In addition, future research could 
assess whether improved opioid prescribing could also help reduce opioid misuse and opioid 
overdoses involving alcohol. In addition, future research could assess whether improved 
opioid prescribing could also help reduce opioid misuse and opioid overdoses involving 
alcohol.
Limitations
This study has limitations. First, this study was not able to examine whether alcohol and 
opioids were used concurrently. Second, data were based on self-reports, and therefore, both 
prescription opioid misuse and alcohol consumption (particularly binge drinking) are likely 
to have been underreported. However, the NSDUH audio computer-assisted self-interview 
process assesses the internal consistency of responses, which has been shown to improve the 
sensitivity of NSDUH estimates of binge drinking among adults.37 Third, because this study 
was focused on the misuse of prescription opioids, it did not consider the use of illicit 
opioids, such as heroin and illicitly manufactured fentanyl, which has been increasing,38 
including among people who binge drink and people who misuse prescription opioids.39
CONCLUSIONS
Binge drinking is associated with prescription opioid misuse, and the prevalence of 
prescription opioid misuse increased with the frequency of binge drinking. Binge drinkers 
who misuse prescription opioids are likely to be at substantially increased risk of overdose 
because of the combined effect of high blood alcohol levels and prescription opioids on the 
central nervous system.17 The high prevalence, frequency, and intensity of binge drinking 
among adults and adolescents in the U.S.,13,40 along with the heightened prevalence of 
prescription opioid misuse among binge drinkers, emphasizes the importance of adopting a 
comprehensive and coordinated approach to addressing both binge drinking and prescription 
opioid misuse to reduce the risk of opioid overdoses.
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Figure 1. 
Prevalence and 95% CIa of past 30-day prescription opioid misuseb by age group and binge 
drinking frequencyc among binge drinkers.
a95% CIs denoted by bracketed lines on each bar.
bUsed a prescription opioid without a prescription or used only for the experience or feeling 
it caused ≥1 time in the past 30 days.
cNumber of days consuming ≥5 drinks (men) or ≥4 drinks (women), per occasion, in the 
past 30 days.
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Table 3.
Odds of Reporting Past-30 Day Prescription Opioid Misusea by Drinking Pattern and Characteristics
Drinking pattern and characteristics Unadjusted ORs AORse
OR (95% CI) p-value AOR (95% CI) p-value
Drinking pattern
 Non-drinkingb ref ref
 Current drinking/non-bingec 1.0 (0.8, 1.2) 0.869 1.0 (0.8, 1.1) 0.580
 Binge drinkingd 3.4 (3.0, 3.9) <0.001 1.7 (1.5, 1.9) <0.001
Sex
 Male 1.3 (1.2, 1.5) <0.001 1.0 (0.9, 1.2) 0.871
 Female ref ref
Age group, years
 12–17 2.1 (1.7, 2.7) <0.001 2.2 (1.7, 2.8) <0.001
 18–25 3.8 (3.1, 4.6) <0.001 1.7 (1.4, 2.1) <0.001
 26–34 3.5 (2.8, 4.5) <0.001 2.0 (1.6, 2.6) <0.001
 35–49 2.1 (1.7, 2.7) <0.001 1.6 (1.3, 2.1) <0.001
 ≥50 ref ref
Race or ethnicity
 White, non-Hispanic 1.6 (1.3, 2.0) <0.001 1.4 (1.1, 1.8) <0.01
 Black, non-Hispanic 1.9 (1.4, 2.5) <0.001 1.5 (1.1, 2.1) <0.01
 Hispanic or Latino 1.5 (1.2, 2.0) <0.01 1.3 (1.0, 1.8) <0.05
 Otherf ref ref
Family income (annual)
 <$20,000 1.8 (1.5, 2.2) <0.001 1.3 (1.1, 1.5) <0.01
 $20,000–<$50,000 1.4 (1.2, 1.6) <0.001 1.2 (1.0, 1.4) 0.111
 $50,000–<$75,000 1.1 (0.9, 1.3) 0.332 1.0 (0.8, 1.2) 0.993
 ≥$75,000 ref ref
Rural or urban statusg
 Large metropolitan 1.3 (1.1, 1.6) <0.01 1.3 (1.1, 1.6) <0.01
 Small metropolitan 1.4 (1.2, 1.7) <0.001 1.4 (1.2, 1.6) <0.001
 Nonmetropolitan ref ref
Other substance use
 Cigaretteh 4.1 (3.7, 4.5) <0.001 2.1 (1.9, 2.4) <0.001
 Marijuanai 8.8 (7.8, 10.0) <0.001 4.6 (4.0, 5.3) <0.001
Notes: Boldface indicates statistical significance (p<0.05).
aUsed an opioid pain reliever without a prescription or used only for the experience or feeling it caused ≥1 time in the past 30 days.
b
Did not consume an alcoholic drink on any day in past 30 days, including lifetime abstainers.
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cConsumed ≥1 alcoholic drink on ≥1 day but did not consume ≥5 drinks (men) or ≥4 drinks (women), per occasion, on at ≥1 day in the past 30 
days.
dConsumed ≥5 drinks (men) or ≥4 drinks (women), per occasion, on ≥1 day in the past 30 days.
e
Multivariable logistic regression models adjusted for sex, age group, race or ethnicity, total annual family income, rural or urban status, cigarette 
use, and marijuana use.
f
Including Asian, American Indian, Alaskan Native, Native Hawaiian or other Pacific Islander, or more than one race or ethnicity.
g
Based on the “Rural/Urban Continuum Codes” developed in 2003 by the U.S. Department of Agriculture. Large metropolitan counties have a total 
population of 1 million or more. Small metropolitan counties have a total population of fewer than 1 million. Nonmetropolitan areas include 
counties in micropolitan statistical areas as well as counties outside of both metropolitan and micropolitan statistical areas.19
hSmoked part or all of a cigarette in the past 30 days.
iUsed marijuana or hashish in the past 30 days.
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